CARSO Group has acquired Bactéries et Aliments
CARSO Group has strengthened its leadership in the food safety sector through the acquisition of Bactéries et Aliments.
Established in 1992 and headquartered in France, CARSO is one of the leading providers of analytical services in the French market, with operations in several neighboring countries. The company offers a broad range of analyses, including water and environmental testing, occupational hygiene and building health, food safety, genetic testing and pharmaceutical analysis. In 2021, ARCHIMED became CARSO’s majority shareholder, in partnership with CAPZA, Siparex, the management team and the company’s founders. Since then, ARCHIMED has supported CARSO’s organic and external growth across Europe through targeted acquisitions and strategic partnerships in high-potential market segments. The shared objective is to further strengthen CARSO’s position as an independent, entrepreneurial and international platform in the analytical services industry.
Founded over 20 years ago, Bactéries et Aliments is a laboratory specializing in microbiological analysis. It is recognized in the field of food hygiene for its customized services, expert guidance and cutting-edge R&D activities that support development projects within the food industry.
Oaklins’ team in France advised CARSO and its shareholders on the acquisition of Bactéries et Aliments.
Contáctese con el equipo de la transacción
Transacciones relacionadas
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Ver másbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Ver másBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Ver más